

American Association of Clinical Endocrinologists
Texas Chapter of AACE Annual Meeting
and
The Texas Endocrine Surgical Symposium

August 3-4, 2018

JW Marriott Houston
5150 Westheimer Road
Houston, TX, 77056

PROGRAM COMMITTEE

Tiana Shiver, MD, FACE; Program Co-Chair
James Suliburk, MD; Program Co-Chair
Alberto Chavez, MD, MSCI
Brian Chou, MD
Kathleen Hands, MD, FACE, ECNU
Lindsey Harrison, MD, FACE
Kathy Ann LaCivita, MD, FACP, FACE
Kevin McKinney, MD, FACE
Kerem Ozer, FACE, ECNU
Susan Samson, MD, PhD, FRCPC, FACE
Heidi Shea, MD, FACE

Friday, August 3, 2018

7:00 – 8:00 a.m. **Continental Breakfast**

8:00 - 8:30 a.m. **Welcome and pre-meeting assessment**

Session 1-Diabetes/Metabolism

8:30 - 9:05 a.m. **Diabetes and Cancer Risk: Is there a link?**

Sonali Thosani, MD

Objectives:

1. List site specific cancers that are associated with diabetes
2. Discuss possible mechanisms on how diabetes confers increased risk
3. Discuss controversies in regards to drugs used to treat diabetes and how they affect cancer risk/outcome

9:05 - 9:40 a.m. **Nutrition: Overview of popular diets**

Scott Isaacs, MD, FACP, FACE

Objectives:

1. Explain the pros and cons of various diets such as plant-based diets, low-carbohydrate diets, Mediterranean diet, balanced diet, low fat diet, etc.
2. Understand nutrition treatment of diseases like obesity, diabetes, dyslipidemia and cardiovascular disease
3. Counsel patients on the fundamentals of nutrition to address all aspects of health and disease

9:40 - 10:15 a.m. **Lipid Guidelines Comparison**

Nicola Abate, MD

Objectives:

1. Understand available lipid guidelines
2. Understand differences between lipid guidelines
3. Understand how to apply current guidelines for cardiovascular disease prevention

10:15 - 10:45 a.m.	Break
10:45 - 11:20 a.m.	Continuous Glucose Monitoring: Are we there yet? Current uses and future directions Pablo Mora, MD, CDE, FACE Objectives: 1. Discuss the different available technologies to monitor glucose from the interstitial fluid and its technical advantages and limitations 2. Integration of CGM with current therapies and upcoming applications 3. Clinical scenarios for best practices of CGM
11:20 - 11:55 a.m.	Some Cases from the Office: Next steps? Brian Michael, MD, FACE, ECNU Objectives: 1. Recognizing and managing endocrine conditions with atypical or unusual clinical presentations 2. Increasing awareness of newer diagnostic testing modalities 3. Increasing awareness of alternative testing and treatment approaches for common endocrine problems
12:30 - 2:00 p.m.	Lunch
Session 2- Pituitary/Reproductive	
2:00 - 2:35 p.m.	It's Not a Tumor: Update on hypophysitis Susan Samson, MD, PhD, FRCPC, FACE Objectives: 1. Recognize the imaging characteristics and clinical findings which accompany hypophysitis 2. Describe the presentation and characteristics of more recently characterized forms of hypophysitis 3. Discuss options for management of hypophysitis of different origins.
2:35 - 3:05 p.m.	Minimally Invasive Endoscopic Resection of Pituitary Tumors: A neurosurgeon's perspective Daniel Yoshor, MD Objectives: 1. Describe the technical advances in pituitary surgery over the last decade, particularly the endonasal endoscopic approach to sellar masses 2. Discuss the predictors of remission/cure in patients with functional tumors including prolactinomas, somatotropinomas, and corticotropinomas 3. Recognize the indications for surgical intervention of tumors that previously would have been treated medically, including prolactinomas
3:05 - 3:40 p.m.	Break
3:40 - 4:15 p.m.	Controversies with the Diagnosis and Treatment of Hypogonadism Mohit Khera, MD Objectives: 1. Understand the relationship between testosterone replacement therapy and the effects on the prostate 2. Be familiar with the FDA warnings for cardiovascular disease and indication for use of testosterone 3. Understand the relationship between testosterone and male fertility
4:15 - 4:45 p.m.	Post Meeting Assessment
4:45 - 5:30 p.m.	Business Meeting

Saturday, August 4, 2018

6:45 – 7:40 a.m. **Continental Breakfast**

7:40 - 8:05 a.m. **Welcome/Pre-Meeting Assessment**

Session 3 - Thyroid Section

8:05 - 8:40 a.m. **Interferences with Endocrine Tests**

Carole Spencer, PhD, FACB, MTC

Objectives:

1. Review the causes of non-specific and analyte-specific interferences affecting Endocrine Tests
2. Discuss why test interferences should be suspected by the physician and not the laboratory
3. Discuss approaches for confirming interference affecting a test result.

8:40 - 9:45 a.m.

What's A NIFTP, Keeping Up to Date in Thyroid 2018

Kathleen Hands, MD, FACE, ECNU

Objectives:

1. Learn the new AJCC edition
2. Understand the new Bethesda changes
3. Become familiar new nomenclature for NIFTP

9:45 - 10:05 a.m.

Thyroid Cancer Case Review Panel

James Suliburk, MD, FACS

Objectives:

1. Apply ATA 2015 Guidelines for extent of resection
2. Use ATA guidelines in given clinical scenarios to determine evidence-based therapy recommendations
3. Make recommendations for appropriate use of I131

10:05 - 10:35 a.m.

Break

10:35 - 11:10 a.m.

Management of Vocal Paralysis - Raising Voices in Texas Endocrine Surgery

Kenneth Altman, MD, PhD, FACS

Objectives:

1. Determine the etiology and prevalence of vocal immobility related to thyroid disease and its surgery
2. Be able to identify and quantify vocal immobility and its clinical consequences
3. Understand management options including surgery for vocal fold immobility

11:10 - 12:00 p.m.

Panel Discussion

12:00 - 1:30 p.m.

Lunch

Session 4- Adrenal/Bone

1:30 - 2:15 p.m.

Pheochromocytoma and Paraganglioma: Focus on therapeutics

Camillo Jimenez, MD

Objectives:

1. Learn how to prepare patients for surgery
2. Learn how to treat a hypertensive crisis
3. Learn how to approach patients with malignant pheochromocytoma and paraganglioma

2:15 - 2:45 p.m.

New Radio Pharmaceuticals in the Diagnosis and Treatment of Neuroendocrine Cancers (NEC) (NON-CME)

Ebrahim Delpassand, MD, FACN

Objectives:

1. Classification of NEC
2. Radiopharmaceuticals used in diagnoses of NEC
3. Radiopharmaceuticals used in treatment of NEC

2:45 - 3:20 p.m.

Bone Health in Patients with Chronic Kidney Disease: Evaluation and management

Naim Maalouf, MD

Objectives:

1. Identify major risk factors for osteoporosis and osteoporotic fractures in patients with chronic kidney disease
2. Recognize the recommended evaluation of skeletal health in patients with chronic kidney disease
3. Assess the risk and benefits of pharmacological interventions to reduce fracture risk in patients with chronic kidney disease

3:20 - 3:55 p.m.

Fellow Talks

3:55 - 4:30 p.m.

Post-Meeting Assessment/Adjourn